44. 多発血管炎性肉芽腫症 Disease details / Clinical trials / Drug dev / DR info

0 MG prednisone
   University of Pennsylvania
      2014   Phase 3   NCT01940094   Canada;United States
   University of South Florida
      2014   Phase 3   NCT01933724   United States
5 MG prednisone
   University of Pennsylvania
      2014   Phase 3   NCT01940094   Canada;United States
   University of South Florida
      2014   Phase 3   NCT01933724   United States
AB-101
   IRIS Research and Development, LLC
      2024   Phase 1   NCT06581562   United States
Abatacept
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 2   EUCTR2021-000679-35-FR   France
   Univeristy of South Florida
      2016   Phase 3   EUCTR2013-005535-24-GB   Australia;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States
   University of South Florida
      2016   Phase 3   EUCTR2013-005535-24-IE   Australia;Belgium;Canada;France;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States
      2015   Phase 3   NCT02108860   Canada;Germany;Ireland;United Kingdom;United States
      -   Phase 3   EUCTR2013-005535-24-DE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States
Active comparator
   Novartis Pharmaceuticals
      2025   Phase 2   NCT06868290   Israel;Japan;Singapore;United States
   University of Miyazaki Hospital
      2014   Phase 3   JPRN-UMIN000012409   Japan,North America,South America,Australia,Europe
Alemtuzumab
   Cambridge University Hospitals NHS Foundation Trust
      2011   Phase 4   NCT01405807   United Kingdom
ANTI-interleukin 5 (IL-5) humanized monoclonal
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2022   Phase 3   EUCTR2021-005726-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-005726-15-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
Avacopan
   CHEMOCENTRYX, INC.
      2017   Phase 3   EUCTR2016-001121-14-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
   ChemoCentryx, Inc.
      2017   Phase 3   EUCTR2016-001121-14-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NO   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NL   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-AT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-FR   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
   Kissei Pharmaceutical Co., Ltd.
      2022   -   NCT06758271   Japan
Azathioprin-ratiopharm® 25 MG filmtabletten
   Nordic Pharma France
      2011   -   EUCTR2011-001219-30-SE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-ES   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-CZ   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Nordic Pharma SAS
      2012   -   EUCTR2011-001219-30-DE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-SK   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2011-001219-30-GB   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
Azathioprine
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 2   EUCTR2021-000679-35-FR   France
      2021   Phase 3   EUCTR2020-003318-10-FR   France
      2016   Phase 3   EUCTR2016-000627-53-FR   France
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03164473   France
      2008   Phase 3   NCT00748644   France
   Cambridge University Hospitals NHS Foundation Trust
      2013   Phase 3   NCT01697267   Australia;Canada;Czech Republic;Czechia;Ireland;Italy;Japan;New Zealand;Sweden;United Kingdom;United States
   Tokyo women's medical university Institute of rheumatology
      2018   Phase 2   JPRN-UMIN000024574   Japan
   University of Miyazaki Hospital
      2014   Phase 3   JPRN-UMIN000012409   Japan,North America,South America,Australia,Europe
Azathioprine 25 MG
   Nordic Pharma France
      2011   -   EUCTR2011-001219-30-SE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-ES   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-CZ   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Nordic Pharma SAS
      2012   -   EUCTR2011-001219-30-DE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-SK   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2011-001219-30-GB   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
AZD7986
   Insmed Incorporated
      2019   Phase 2   EUCTR2018-003903-21-FR   France
Belimumab
   Rachel Jones
      2019   Phase 2   NCT03967925   United Kingdom
Benralizumab
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca
      2025   Phase 3   NCT06512883   Brazil;Canada;Mexico;Turkey;United States
      2019   Phase 3   NCT04157348   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca KK
      2019   Phase 3   JPRN-jRCT2080224961   Belgium;Canada;France;Germany;Israel;Italy;United Kingdom;United States of Amerika
   National Jewish Health
      2017   Phase 2   NCT03010436   United States
Blisibimod
   Anthera Pharmaceuticals
      2014   Phase 2   NCT01598857   -
CCX168
   CHEMOCENTRYX, INC.
      2017   Phase 3   EUCTR2016-001121-14-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
   ChemoCentryx, Inc.
      2017   Phase 3   EUCTR2016-001121-14-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NO   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NL   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-AT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-FR   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
Chimeric monoclonal antibody, IGG4 subtype
   InflaRx GmbH
      2019   Phase 2   EUCTR2018-000768-27-SE   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-NL   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-IT   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-IE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-GB   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-ES   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-DK   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-DE   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-CZ   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-BE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
Corticosteroid and azathioprine
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00647166   France
Cyclophosphamide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 3   EUCTR2020-003318-10-FR   France
      2016   Phase 3   EUCTR2016-000275-25-FR   France
   Amano Koichi
      2023   Phase 3   JPRN-jRCT2041220136   -
   Assistance Publique - Hôpitaux de Paris
      2016   Phase 3   NCT02807103   France
   IRIS Research and Development, LLC
      2024   Phase 1   NCT06581562   United States
   Masayoshi Harigai
      2018   Phase 2   JPRN-jRCT1091220325   Japan
   Nordic Pharma France
      2011   -   EUCTR2011-001219-30-SE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-ES   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-CZ   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Nordic Pharma SAS
      2012   -   EUCTR2011-001219-30-DE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-SK   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2011-001219-30-GB   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Ottawa Hospital Research Institute
      2025   Phase 3   NCT06983821   Canada
Cyclophosphamide followed BY methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
   Nordic Pharma SAS
      2011   Phase 3   NCT01446211   Czech Republic
Cyclophosphamide/azathioprine
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 3   NCT05030155   France
Cyclophosphamidum 500 MG
   Nordic Pharma France
      2011   -   EUCTR2011-001219-30-SE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-ES   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-CZ   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Nordic Pharma SAS
      2012   -   EUCTR2011-001219-30-DE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-SK   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2011-001219-30-GB   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
Depemokimab
   Fujii Katsuya
      2022   Phase 3   JPRN-jRCT2031220070   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Poland;Portugal;South Korea;Spain;Sweden;USA;United kingdom
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2022   Phase 3   EUCTR2021-005726-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline
      2022   Phase 3   NCT05263934   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-005726-15-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
Endoxan® 500 MG
   Nordic Pharma France
      2011   -   EUCTR2011-001219-30-SE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-ES   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-CZ   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Nordic Pharma SAS
      2012   -   EUCTR2011-001219-30-DE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-SK   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2011-001219-30-GB   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
Fasenra
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
Fludarabine
   IRIS Research and Development, LLC
      2024   Phase 1   NCT06581562   United States
Galen® tablet
   InflaRx GmbH
      2019   Phase 2   EUCTR2018-000768-27-NL   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-IT   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-ES   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-BE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
Glucocorticoids
   Chiba University
      2014   Phase 4   NCT02198248   Japan
   InflaRx GmbH
      2019   Phase 2   EUCTR2018-000768-27-SE   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-NL   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-IT   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-IE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-ES   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-DK   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-DE   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-CZ   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-BE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
   Massachusetts General Hospital
      2014   Phase 4   NCT02169219   United States
   Novartis Pharmaceuticals
      2025   Phase 2   NCT06868290   Israel;Japan;Singapore;United States
   University of Pennsylvania
      2010   Phase 3   NCT00987389   Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Greece;Italy;Japan;Mexico;New Zealand;Norway;Sweden;United Kingdom;United States
Glucocorticoids - reduced dose
   University of Pennsylvania
      2010   Phase 3   NCT03919825   -
Glucocorticoids - standard dose
   University of Pennsylvania
      2010   Phase 3   NCT03919825   -
GSK3511294
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2022   Phase 3   EUCTR2021-005726-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-005726-15-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
Gusperimus
   Nordic Pharma France
      2011   -   EUCTR2011-001219-30-SE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-ES   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-CZ   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Nordic Pharma SAS
      2012   -   EUCTR2011-001219-30-DE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-SK   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2011-001219-30-GB   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
Gusperimus + glucocorticoids
   Nordic Pharma SAS
      2011   Phase 3   NCT01446211   Czech Republic
Hydroxychloroquine
   Guy's and St Thomas' NHS Foundation Trust
      2020   Phase 4   NCT04316494   United Kingdom
Idefirix
   Charité - Universitätsmedizin Berlin
      2023   Phase 2   EUCTR2021-004706-22-DE   Germany
IFX-1
   InflaRx GmbH
      2019   Phase 2   NCT03895801   Belgium;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-SE   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-NL   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-IT   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-IE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-GB   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-ES   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-DK   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-DE   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-CZ   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-BE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2018   Phase 2   NCT03712345   Canada;United States
Imlifidase
   Charité - Universitätsmedizin Berlin
      2023   Phase 2   EUCTR2021-004706-22-DE   Germany
Immunoglobulin G cleaving cystein protease derived from E. coli
   Charité - Universitätsmedizin Berlin
      2023   Phase 2   EUCTR2021-004706-22-DE   Germany
Imurel
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 3   EUCTR2020-003318-10-FR   France
Imurel 25 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000627-53-FR   France
INS1007
   Insmed Incorporated
      2019   Phase 2   EUCTR2018-003903-21-FR   France
L04ac06
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
Laboratory experiments before and after mepolizumab treatment
   University Medical Center Groningen
      2024   -   NCT06298448   Netherlands
Mabthera
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000627-53-FR   France
   F. HOFFMANN - LA ROCHE LTD.
      2013   Phase 2   EUCTR2012-002062-13-IT   Germany;Italy;Turkey;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2013   Phase 2   EUCTR2012-002062-13-GB   Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2012-002062-13-DE   Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States
MEDI-563
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
Meperizumab injection
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2022   Early Phase 1   NCT05353179   China
Mepolizumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 3   EUCTR2020-003318-10-FR   France
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   Assistance Publique - Hôpitaux de Paris
      2022   Phase 3   NCT05030155   France
   AstraZeneca
      2019   Phase 3   NCT04157348   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca KK
      2019   Phase 3   JPRN-jRCT2080224961   Belgium;Canada;France;Germany;Israel;Italy;United Kingdom;United States of Amerika
   Fujii Katsuya
      2022   Phase 3   JPRN-jRCT2031220070   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Netherlands;Poland;Portugal;South Korea;Spain;Sweden;USA;United kingdom
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2022   Phase 3   EUCTR2021-005726-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline
      2022   Phase 3   NCT05263934   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   NCT03298061   Belgium;Canada;France;Germany;Japan;United Kingdom;United States
      2014   Phase 3   NCT02020889   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
   GlaxoSmithKline Research & Development Ltd
      2014   Phase 3   EUCTR2012-004385-17-IT   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2012-004385-17-DE   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004385-17-GB   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004385-17-BE   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-005726-15-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline Research Ltd
      2015   Phase 3   EUCTR2014-003162-25-GB   Belgium;Canada;France;Germany;Japan;United Kingdom
      2015   Phase 3   EUCTR2014-003162-25-DE   Belgium;Canada;France;Germany;Japan;United Kingdom
      2015   Phase 3   EUCTR2014-003162-25-BE   Belgium;Canada;Germany;Japan;United Kingdom;United States
   GlaxoSmithKline, S.A.
      2014   Phase 3   EUCTR2012-004385-17-ES   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
   Taniguchi Masami
      2024   Phase 4   JPRN-jRCTs031230675   -
Mesna
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000275-25-FR   France
Metex 2,5 MG tabletten
   Nordic Pharma France
      2011   -   EUCTR2011-001219-30-SE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-ES   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-CZ   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Nordic Pharma SAS
      2012   -   EUCTR2011-001219-30-DE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-SK   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2011-001219-30-GB   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
Methotrexate
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 2   EUCTR2021-000679-35-FR   France
   Shanghai Zhongshan Hospital
      2021   Phase 4   NCT04944524   China
Methotrexate 2.5 MG
   Nordic Pharma France
      2011   -   EUCTR2011-001219-30-SE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-ES   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-CZ   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Nordic Pharma SAS
      2012   -   EUCTR2011-001219-30-DE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-SK   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2011-001219-30-GB   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
Methotrexate 25 MG
   Nordic Pharma France
      2011   -   EUCTR2011-001219-30-SE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-ES   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-CZ   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Nordic Pharma SAS
      2012   -   EUCTR2011-001219-30-DE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-SK   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2011-001219-30-GB   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
Metoject 10 MG/ML, solution injectable EN seringue PRé-remplie
   Nordic Pharma France
      2011   -   EUCTR2011-001219-30-SE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-ES   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-CZ   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
   Nordic Pharma SAS
      2012   -   EUCTR2011-001219-30-DE   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   -   EUCTR2011-001219-30-SK   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2011-001219-30-GB   Czech Republic;France;Germany;Italy;Netherlands;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
Mycophenolate mofetil
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 2   EUCTR2021-000679-35-FR   France
Mycophénolate MOFéTIL
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 2   EUCTR2021-000679-35-FR   France
Naltrexone hydrochloride
   University of Pennsylvania
      2019   Phase 2   NCT03482479   Canada;United States
NO plasma exchange
   University of Pennsylvania
      2010   Phase 3   NCT00987389   Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Greece;Italy;Japan;Mexico;New Zealand;Norway;Sweden;United Kingdom;United States
NS-229
   NS Pharma, Inc.
      2023   Phase 2   NCT06046222   Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
Nucala
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-001832-77-IT   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-BE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-GB   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001832-77-FR   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2022   Early Phase 1   NCT05353179   China
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2022   Phase 3   EUCTR2021-005726-15-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
   GlaxoSmithKline Research & Development Ltd
      2013   Phase 3   EUCTR2012-004385-17-GB   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-005726-15-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2021-005726-15-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
Nucala 100 MG powder FOR solution FOR injection
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-001832-77-DE   Belgium;Canada;France;Germany;Israel;Italy;Japan;United Kingdom;United States
Obinutuzumab
   Assistance Publique - Hôpitaux de Paris
      2025   Phase 2   NCT06940661   France
   Mayo Clinic
      2023   Phase 2   NCT05376319   United States
Orencia
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 2   EUCTR2021-000679-35-FR   France
   Univeristy of South Florida
      2016   Phase 3   EUCTR2013-005535-24-GB   Australia;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States
   University of South Florida
      2016   Phase 3   EUCTR2013-005535-24-IE   Australia;Belgium;Canada;France;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2013-005535-24-DE   Australia;Belgium;Canada;France;Germany;Ireland;Italy;Mexico;Spain;Sweden;Switzerland;United Kingdom;United States
Pednisone
   ChemoCentryx, Inc.
      2017   Phase 3   EUCTR2016-001121-14-NO   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NL   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-FR   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
Plaquenil - hydroxychloroquine 200MG film coated tablets
   Guy's and St. Thomas' NHS Foundation Trust
      2020   Phase 4   EUCTR2018-001268-40-GB   United Kingdom
Prednisolone
   GlaxoSmithKline
      2015   Phase 3   NCT03298061   Belgium;Canada;France;Germany;Japan;United Kingdom;United States
   Masayoshi Harigai
      2018   Phase 2   JPRN-jRCT1091220325   Japan
   Rachel Jones
      2019   Phase 2   NCT03967925   United Kingdom
Prednison acis® 20 MG
   ChemoCentryx, Inc.
      2017   Phase 3   EUCTR2016-001121-14-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NO   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NL   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-AT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-FR   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
Prednison acis® 5 MG
   ChemoCentryx, Inc.
      2017   Phase 3   EUCTR2016-001121-14-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NO   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NL   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-AT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-FR   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
Prednison acis¿ 20 MG
   CHEMOCENTRYX, INC.
      2017   Phase 3   EUCTR2016-001121-14-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
Prednison acis¿ 5 MG
   CHEMOCENTRYX, INC.
      2017   Phase 3   EUCTR2016-001121-14-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
Prednisone
   CHEMOCENTRYX, INC.
      2017   Phase 3   EUCTR2016-001121-14-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
   ChemoCentryx, Inc.
      2017   Phase 3   EUCTR2016-001121-14-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NO   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-NL   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2016-001121-14-AT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-FR   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2016-001121-14-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Spain;Sweden;Switzerland;United Kingdom;United States
   Hospices Civils de Lyon
      2018   Phase 3   EUCTR2018-001215-69-FR   France
   Ottawa Hospital Research Institute
      2025   Phase 3   NCT06983821   Canada
Prednisone tablets, USP
   InflaRx GmbH
      2019   Phase 2   EUCTR2018-000768-27-SE   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-NL   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-IT   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-IE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-GB   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-ES   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-DK   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-DE   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-CZ   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-BE   Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
Procalcitonin-variants elisa-assay
   University Hospital Muenster
      2022   -   NCT05703802   Germany
Rapcabtagene autoleucel
   Novartis Pharmaceuticals
      2025   Phase 2   NCT06868290   Israel;Japan;Singapore;United States
Recombinant humanized monoclonal antibody specific FOR human IL-5
   GlaxoSmithKline Research & Development Ltd
      2014   Phase 3   EUCTR2012-004385-17-IT   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2012-004385-17-DE   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004385-17-GB   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004385-17-BE   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
   GlaxoSmithKline, S.A.
      2014   Phase 3   EUCTR2012-004385-17-ES   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
Reslizumab
   National Jewish Health
      2017   Phase 2   NCT02947945   United States
Rituximab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 2   EUCTR2021-000679-35-FR   France
      2016   Phase 3   EUCTR2016-000627-53-FR   France
      2016   Phase 3   EUCTR2016-000275-25-FR   France
   Amano Koichi
      2023   Phase 3   JPRN-jRCT2041220136   -
   Assistance Publique - Hôpitaux de Paris
      2025   Phase 3   NCT04871191   France
      2018   Phase 3   NCT03164473   France
      2016   Phase 3   NCT02807103   France
      2012   Phase 3   NCT01731561   France
      2008   Phase 3   NCT00748644   France
   CHU de Saint-Etienne
      2015   Phase 4   EUCTR2015-001807-29-FR   France
   Cambridge University Hospitals NHS Foundation Trust
      2013   Phase 3   NCT01697267   Australia;Canada;Czech Republic;Czechia;Ireland;Italy;Japan;New Zealand;Sweden;United Kingdom;United States
   Chiba University
      2014   Phase 4   NCT02198248   Japan
   F. HOFFMANN - LA ROCHE LTD.
      2013   Phase 2   EUCTR2012-002062-13-IT   Germany;Italy;Turkey;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2013   Phase 2   EUCTR2012-002062-13-GB   Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2012-002062-13-DE   Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States
   Genentech, Inc.
      2012   -   NCT01613599   United States
   Hoffmann-La Roche
      2013   Phase 2   NCT01750697   Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States
   Hospital for Special Surgery, New York
      2015   Phase 4   NCT02626845   United States
   IRIS Research and Development, LLC
      2024   Phase 1   NCT06581562   United States
   Massachusetts General Hospital
      2014   Phase 4   NCT02169219   United States
   Mayo Clinic
      2023   Phase 2   NCT05376319   United States
   Ottawa Hospital Research Institute
      2025   Phase 3   NCT06983821   Canada
   Rachel Jones
      2019   Phase 2   NCT03967925   United Kingdom
   University of Miyazaki Hospital
      2014   Phase 3   JPRN-UMIN000012409   Japan,North America,South America,Australia,Europe
RO0452294/V01
   F. HOFFMANN - LA ROCHE LTD.
      2013   Phase 2   EUCTR2012-002062-13-IT   Germany;Italy;Turkey;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2013   Phase 2   EUCTR2012-002062-13-GB   Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2012-002062-13-DE   Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States
RO0452294/V02
   F. HOFFMANN - LA ROCHE LTD.
      2013   Phase 2   EUCTR2012-002062-13-IT   Germany;Italy;Turkey;United Kingdom;United States
   F. Hoffmann-La Roche Ltd.
      2013   Phase 2   EUCTR2012-002062-13-GB   Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States
      2013   Phase 2   EUCTR2012-002062-13-DE   Canada;France;Germany;Italy;Serbia;Turkey;United Kingdom;United States
Roactemra
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 2   EUCTR2021-000679-35-FR   France
SB-240563
   GlaxoSmithKline Research & Development Ltd
      2014   Phase 3   EUCTR2012-004385-17-IT   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2012-004385-17-DE   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004385-17-GB   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2012-004385-17-BE   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
   GlaxoSmithKline Research Ltd
      2015   Phase 3   EUCTR2014-003162-25-GB   Belgium;Canada;France;Germany;Japan;United Kingdom
      2015   Phase 3   EUCTR2014-003162-25-DE   Belgium;Canada;France;Germany;Japan;United Kingdom
      2015   Phase 3   EUCTR2014-003162-25-BE   Belgium;Canada;Germany;Japan;United Kingdom;United States
   GlaxoSmithKline, S.A.
      2014   Phase 3   EUCTR2012-004385-17-ES   Belgium;Canada;France;Germany;Italy;Japan;Spain;United Kingdom;United States
SHR-1703
   Guangdong Hengrui Pharmaceutical Co., Ltd
      2023   Phase 2/Phase 3   NCT05979051   China
Tezepelumab
   Imperial College London
      2024   Phase 2   NCT06230354   United Kingdom
Tocilizumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 2   EUCTR2021-000679-35-FR   France
   Assistance Publique - Hôpitaux de Paris
      2025   Phase 3   NCT04871191   France
Tofacitinib
   Assistance Publique - Hôpitaux de Paris
      2025   Phase 3   NCT04871191   France
   Shanghai Zhongshan Hospital
      2021   Phase 4   NCT04944524   China
Trimethoprim sulfamethoxazole
   University of Pennsylvania
      2019   Phase 1/Phase 2   NCT03919435   United States
Vilobelimab
   InflaRx GmbH
      2019   Phase 2   EUCTR2018-000768-27-SE   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-NL   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-DE   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-000768-27-CZ   Belgium;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Russian Federation;Spain;Sweden;United Kingdom
Vitamin D
   Christian Pagnoux
      2020   -   NCT04280601   Canada
Yellow fever vaccine
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil